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Abstract
Diagnosing and treating Alzheimer’s and other diseases associated with amyloid fibers remains a great challenge despite
intensive research. To aid in this effort, we present atomic structures of fiber-forming segments of proteins involved in
Alzheimer’s disease in complex with small molecule binders, determined by X-ray microcrystallography. The fiber-like
complexes consist of pairs of b-sheets, with small molecules binding between the sheets, roughly parallel to the fiber axis.
The structures suggest that apolar molecules drift along the fiber, consistent with the observation of nonspecific binding to
a variety of amyloid proteins. In contrast, negatively charged orange-G binds specifically to lysine side chains of adjacent
sheets. These structures provide molecular frameworks for the design of diagnostics and drugs for protein aggregation
diseases.
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Introduction
The challenge of developing chemical interventions for
Alzheimer’s disease has proceeded in a virtual vacuum of
information about the three-dimensional structures of the two
proteins most widely accepted as being involved in the etiology.
These are amyloid-beta (Ab) and tau [1,2]. Both convert from
largely natively disordered, soluble forms to toxic oligomers and
fibers [2,3] that may be related in structure [4]. Indeed, analogs of
the well-established ligands to amyloid fibers, congo-red and
thioflavin T, also bind Ab oligomers labeling them in vitro and in
vivo [5]. Screens of chemical libraries have uncovered dozens of
small molecules that interact with amyloid [6–8]. Curcumin and
various antibiotics are a few of many fiber inhibitors that also
inhibit oligomer formation [7,9,10], supporting a common
underlying structure in fibers and oligomers. Despite this progress,
until now there have been no atomic-level structures showing how
small molecules bind to amyloid and, consequently, no means for
structure-based design of specific binders.
More is known about the molecular structure of amyloid fibers,
both those associated with Alzheimer’s disease and with the
numerous other amyloid conditions [11–15]. Common to all
amyloid fibers is their X-ray fiber-diffraction pattern, with two
orthogonal reflections at about 4.8 A ˚ and 10 A ˚ spacing
suggesting a ‘‘cross-b structure’’ [16,17]. The determination of
the first amyloid-like atomic structures revealed a motif consisting
of a pair of tightly mated b-sheets, called a ‘‘steric zipper,’’ which
is formed from a short self-complementary segment of the
amyloid-forming protein [12,18,19]. The steric zipper structures
elucidate the atomic features that give rise to the common cross-b
diffraction pattern, corresponding to the 4.8 A ˚ spacing between
strands forming b-sheets and the ,10 A ˚ spacing between two
mating b-sheets. The structures imply that stacks of identical
short segments form the ‘‘cross-b spine’’ of the protofilament, the
basic unit of the mature fiber, while the rest of the protein adopts
either native-like or unfolded conformations peripheral to the
spine [12,20].
The short segments forming steric zippers, when isolated from
the rest of the protein, form well-ordered fibers on their own, with
essentially all properties of the fibers of their full-length parent
proteins [21,22]. These properties include similar fiber diameters
and helical pitch, similar cross-b diffraction patterns, similar fiber-
seeding capacities, similar stability, and similar dye binding. That
stacked short amyloidogenic segments can constitute the entire
spine of an amyloid-like fiber has been demonstrated with the
enzyme RNase A, containing an insert of a short amyloidogenic
segment [20,23]. These RNase A fibers retain enzymatic activity,
showing that native-like structure remains intact with only the
stacked segments forming the spine. Thus while short amyloido-
genic segments cannot recapitulate the entire complexity of their
parent proteins, they nonetheless serve as good models for full
amyloid fibers [24] and offer the informational advantage that
they often grow into microcrystals whose atomic structures can be
determined [12]. To date, structures for over 50 such steric zippers
have been determined from a variety of disease-associated proteins
([18,19,25–27] and Colletier et al. unpublished results).
Here we use one such amyloid-forming segment from Ab and
one from tau to form co-crystals with low molecular weight
PLoS Biology | www.plosbiology.org 1 June 2011 | Volume 9 | Issue 6 | e1001080compounds, with the aim of illuminating the nature of interactions
of small molecules with amyloid. These complexes reveal a
molecular framework which partially defines the amyloid
pharmacophore, the structural features responsible for the binding
of small molecules to amyloid aggregates.
Results
Screening for Co-Crystals of Amyloid-Like Segments with
Small Molecules
In our attempts to obtain complexes of small molecules with
amyloid-like segments from disease-related proteins, we screened
for co-crystals grown from dozens of mixtures (Table S1). The
majority of the resulting crystals yielded X-ray diffraction too
poor for structure determination. Others led to structure
determinations of the small molecule or amyloid-like segment
alone. Out of hundreds of co-crystallization trials (Table S1),
four mixtures, described below, yielded co-crystals with suitable
X-ray diffraction from segments of Ab and tau with amyloid
binders.
Crystal Structure of the KLVFFA Segment from Ab
Complexed with Orange-G
The KLVFFA segment (residues 16–21) from Ab contains
apolar residues that participate in a hydrophobic spine in Ab fibers
and itself acts as an inhibitor of Ab fibrillation [28,29]. We
previously determined the atomic structure of the KLVFFA
segment in three crystal forms; all show the common steric zipper
motif associated with amyloid fibers (Colletier et al. unpublished
results). Orange-G (Figure S1), a synthetic azo dye used in
histological staining, affects the formation of Ab fibers [7]. The co-
crystallization of KLVFFA with orange-G resulted in deeply
colored crystals (Figure 1C). Mass spectrometric analyses of the
crystals showed high abundance of orange-G (,1:1 molar
stoichiometry with KLVFFA). Determination of the structure
revealed a novel, fourth form of the KLVFFA steric zipper, with
orange-G wedged between the paired b-sheets of the zipper,
leading to partial opening of the zipper (Figures 1 and S2).
Stabilization of the binding arises from packing of the aromatic
rings of orange-G against the apolar, partially aromatic spine of
KLVFFA (Figure 2). At the interface between orange-G and
KLVFFA, a total of 500 A ˚ 2 of apolar surface area is covered,
corresponding very roughly to a binding energy of 9 kcal/mol, or a
dissociation constant of ,0.3 mM (Methods). Further stabilization
arises from the salt links between the negatively charged sulfonic
acid groups of orange-G and positively charged lysine side chains
from both b-sheets (Figures 1 and S2). Crystallization of KLVFFA
under identical conditions but without orange-G resulted in the
formation of colorless crystals with a structure similar to Form-1
(Colletier et al. unpublished results and Figures 3A and S3). Thus
the binding of orange-G wedges apart the previously tightly
mating pair of sheets of the steric zipper.
All four crystal forms of KLVFFA, including the complex with
orange G, show an anti-parallel b-strand stacking in the steric
zipper (Colletier et al. unpublished results and Figure 1). Nuclear
magnetic resonance (NMR) characterization of Ab fibers
suggested a parallel orientation of the full-length Ab [30]. Yet
an anti-parallel orientation was proposed for various Ab
segments, both in the region of the KLVFFA segment (residue
numbers are indicated in subscript): Ab16–22 [31], Ab17–21[32],
and Ab11–25 [32], as well as for a segment at the C-terminus:
Ab34–42 [33]. Moreover, the ‘‘Iowa’’ Ab mutant that is related to
a familial, early onset, Alzheimer’s disease [34] also displays an
anti-parallel b-strand orientation. Of potential importance, Ab
oligomers were also suggested to form anti-parallel b-sheet
structures [35,36].
Crystal Structures of the VQIVYK Segment from the Tau
Protein with Orange-G
The VQIVYK segment of tau was suggested as the minimal
interaction motif for fiber formation [37]. We previously
determined the crystal structure of VQIVYK in two crystal
forms; both show the common steric zipper motif of amyloid
fiber-like structures [18,25]. Co-crystallization of VQIVYK with
orange-G resulted in deep orange crystals (Figure 4D). Mass
spectrometric analyses of the crystals showed relatively high
abundance of orange-G (,1:10 molar stoichiometry with
VQIVYK). Determination of the structure revealed a new crystal
form of VQIVYK (Figure 4). Similar to Form-1 [18], the steric
zipper shows a tight and dry interface; yet there is a large void
between pairs of steric zipper, in contrast to the tightly packed
structure of Form-1 (Figure 3D). Orange-G is situated within this
void, binding between lysine side chains facing each other from
two parallel pairs of zippers, forming an electrostatic network that
also involves zinc cations (Figures 4–5). As in its complex with
KLVFFA, orange-G lies with its long axis parallel to the fiber
axis.
Crystallization of VQIVYK alone, under identical conditions
to the co-crystallization of the VQIVYK-orange-G mixture,
resulted in the formation of colorless fibrous crystals (Figure S3)
giving poor X-ray diffraction. Under these conditions, the
presence of orange-G appears crucial for the formation of well-
ordered crystals.
Crystal Structures of the VQIVYK Segment from the Tau
Protein with Curcumin and DDNP
Curcumin (Figure S1) from the plant turmeric protects neuronal
cells against amyloid toxicity [9]. DDNP (Figure S1) [38] and its
analogs, synthetic diagnostics, bind Alzheimer’s-associated neuro-
fibrillary tangles and b-amyloid senile plaques and are used for the
Author Summary
The devastating and incurable dementia known as
Alzheimer’s disease affects the thinking, memory, and
behavior of dozens of millions of people worldwide.
Although amyloid fibers and oligomers of two proteins,
tau and amyloid-b, have been identified in association with
this disease, the development of diagnostics and thera-
peutics has proceeded to date in a near vacuum of
information about their structures. Here we report the first
atomic structures of small molecules bound to amyloid.
These are of the dye orange-G, the natural compound
curcumin, and the Alzheimer’s diagnostic compound
DDNP bound to amyloid-like segments of tau and
amyloid-b. The structures reveal the molecular framework
of small-molecule binding, within cylindrical cavities
running along the b-spines of the fibers. Negatively
charged orange-G wedges into a specific binding site
between two sheets of the fiber, combining apolar binding
with electrostatic interactions, whereas uncharged com-
pounds slide along the cavity. We observed that different
amyloid polymorphs bind different small molecules,
revealing that a cocktail of compounds may be required
for future amyloid therapies. The structures described here
start to define the amyloid pharmacophore, opening the
way to structure-based design of improved diagnostics
and therapeutics.
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[39,40]. Co-crystallization of VQIVYK with either curcumin or
DDNP resulted in yellowish crystals (Figure 6). Similar to Form-
2 of VQIVYK [25], the structures of VQIVYK complexed with
either curcumin or DDNP revealed that in both complexes,
each member of a pair of b-sheets is shifted relative to the other,
partially eliminating the dry interface in the steric zipper
structure (Figures 3E and 6). In both complexes, the electron
density attributed to the small molecule (either curcumin or
DDNP) lies along the void left by the shifting of the steric zipper.
This electron density is too undifferentiated to model the small
molecule in atomic detail. However, it shows that the long axes
of both curcumin and DDNP lie parallel to the fiber axis
(Figures 6–7), as in the KLVFFA and VQIVYK structures with
orange-G.
Despite the lack of differentiated electron density for curcumin
and DDNP in VQIVYK, there is strong evidence for the presence
of the small molecules in the crystals. The crystals show a
distinctive color, whereas the control crystals (grown under
identical condition without the small molecule) are colorless
(Figure S4). The control crystals also lack the additional positive
density attributed to the small molecule (Figure S4). Co-crystals of
VQIVYK and DDNP grown under alternative crystallization
conditions showed a similar positive electron density (Figure S4D),
supporting its attribution to DDNP. Furthermore, the crystals
grown in the presence of DDNP appeared within days, whereas
Figure 1. The crystal structure of the KLVFFA segment from Ab complexed with orange-G. (A–B) The KLVFFA segments are packed as
pairs of b-sheets forming the basic unit of the fiber, namely the steric zipper [12,18]. Here 10 layers of b-strands are depicted; actual fibers contain
,100,000 layers. Orange-G (orange carbons) wedges open the zipper and binds between the pair of b-sheets. KLVFFA and orange-G are shown as
sticks with non-carbon atoms colored by atom type. The b-sheets are composed of anti-parallel strands (cartoon arrows), alternately colored white
and blue. In panel A, the view looks down the fiber axis. In panel B, the view is perpendicular to the fiber axis; the b-strands run horizontally. The
sulfonic acid groups of orange-G form salt links (pink lines) with four lysine residues, two protruding from each facing b-sheet and with a water
molecule shown as an aqua sphere. Only side chain atoms are shown. The unit cell dimension of the crystal along the fiber axis (9.54 A ˚) is indicated.
(C) Micro-crystals of KLVFFA co-crystallized with orange-G. More extensive packing interactions in larger regions of the crystal are presented in Figure
S2.
doi:10.1371/journal.pbio.1001080.g001
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presence of DDNP is a catalyst for crystallization. The strongest
evidence supporting the presence of the small molecules in the
structure is provided by mass spectrometric analyses of the crystals.
The analyses also provided the reasoning for the undifferentiated
electron density, showing a very low molar abundance of both
Figure 2. Binding cavities of orange-G within fibers of the KLVFFA segment from Ab. Orange-G is bound internally to the steric zipper of
KLVFFA (residues 16–21 of Ab). It also contacts the lysine residues in the adjacent zipper. Peptide segments, forming b-sheet structures, are shown as
arrows and sticks, colored by atom type with carbons in white. Orange-G carbons are in orange for one molecule and brown for the other molecule.
Surface is shown for peptide atoms contacting the orange-G molecule with the orange carbons, shown as spheres. The view in (A) looks down the
fiber axis. The view in (B) is perpendicular to the fiber axis. Only side chains of interacting residues are shown. The area of the fiber buried by orange-G
(Methods) is 271 A ˚2 and 272 A ˚2 for the orange and brown colored orange-G, respectively, and is about 80% hydrophobic (contributed by the side
chains of Leu17, Val18, Phe19, and Phe20). The polar interactions are contributed by the charged side chains of Lys16. In (B), one of the b-sheets from
the adjacent pair and one orange-G molecule are removed for clarity.
doi:10.1371/journal.pbio.1001080.g002
Figure 3. Small molecule binding is specific for fiber polymorphism. Three forms of the KLVFFA segment from Ab (A–C) and the VQIVYK
segment from the tau protein (D–F) are presented. These forms serve as examples of packing polymorphism observed for amyloid fibrils [25]. The
view looks down the fiber axis; three layers of depth are depicted. The peptide segments and the small molecules are shown as sticks with non-
carbon atoms colored by atom type. In the KLVFFA forms (A–C), the anti-parallel strands (cartoon arrows) are alternately colored white and blue. The
VQIVYK forms (D–F) pack in parallel b-sheets (represented as cartoon arrows with white carbons). KLVFFA Form-1 (A) and Form-2 (B) (Colletier et al.
unpublished results) and VQIVYK Form-1 (D) [18] are tightly packed such that there are no voids to accommodate binding of small molecules. VQIVYK
Form-2 (E) [25] shows a shift in the steric zipper generating a void that can accommodate the binding of apolar molecules such as curcumin and
DDNP. A docked model of curcumin binding is shown (colored magenta) (Methods). Orange-G binds to unique forms of both KLVFFA and VQIVYK (C
and F), in which large voids are present in the crystal packing. In the KLVFFA complex (C), the binding is internal to the steric zipper, whereas in the
VQIVYK complex (F), the binding is between pairs of b-sheets, i.e., internal to bundles of protofilaments.
doi:10.1371/journal.pbio.1001080.g003
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segments for each curcumin or DDNP molecule, respectively), which
is in close approximation to the experimentally established molar
ratio between FDDNP (the fluoridated version of DDNP) (Figure S1)
and Ab fibril of 1:1500 to 1:3000 [41]. We conjecture that the lack of
site anchoring of the hydrophobic, uncharged small molecules to
specific residues in the fibril leads to undifferentiated electron density.
Furthermore, the nature of the binding site (a narrow tube running
along the b-sheets) (Figures 6–7) implies that the apolar small
molecules are free to drift along the fiber axis (Text S1).
The common feature of the structures of four amyloid/small-
molecule complexes is that the small molecules bind to fibers in a
similar orientation, along the b-sheets, with their long axes parallel
to the fiber axis. This orientation was previously proposed for the
binding of thioflavin T to bovine insulin and bovine b-
lactoglobulin amyloid fibrils using polarized laser confocal
microscopy [42]. A similar mode of binding was seen in co-
crystals of oligomer-like b-2-microglubulin with thioflavin T,
showing that thioflavin T is bound between b-sheets, orthogonal to
the b-strands [43]. The orientation of congo-red was also
Figure 4. The crystal structure of the VQIVYK segment from the tau protein complexed with orange-G. (A–C) The VQIVYK segments
pack in parallel, in-register b-sheets (cartoon arrows) that form steric zippers (two zippers are shown in panel A). Nine layers of the fiber are depicted.
VQIVYK and orange-G are shown as sticks with non-carbon atoms colored by atom type. The carbons of VQIVYK are colored white for one steric
zipper and blue for the other. Two orange-G molecules (orange carbons) mediate contacts between two pairs of steric zippers; that is, orange-G is
located between the protofilaments composing the fiber. In panel A, the view looks down the fiber axis. In panel B, the view is perpendicular to the
fiber axis. Only the two sheets that are in contact with orange-G are shown. Backbone atoms are not shown. The unit cell dimension of the crystal
along the fiber axis (4.83 A ˚) is indicated. The length of orange-G spans multiple unit cells of the fibril; that is, the dimensions of the small molecule
and the fibril unit cell are incommensurate (see Text S1). Panel C is an inset of panel B, focusing on the network of salt links (pink lines) between the
sulfonic acid groups of two orange-G molecules and six lysine residues and with zinc cations (brown spheres). (D) Micro-crystals of VQIVYK co-
crystallized with orange-G.
doi:10.1371/journal.pbio.1001080.g004
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diffraction, linear dichroism [44], and a recent NMR-based model
of congo-red bound to the fungal prion domain HET-s(218–289)
[45].
Discussion
Our crystal structures of small molecules bound within
amyloid-like steric zippers begin to define the molecular
frameworks, or pharmacophores, for the design of diagnostics
and drugs for Alzheimer’s and other aggregation diseases. The
amyloid components in our structures are steric zippers formed
by stacks of six-residue segments from Alzheimer-related
proteins. Although these steric zippers cannot represent all
aspects of the full-length amyloid parent proteins, they share
many properties and are commonly used as models of the
amyloid b-spine and of aggregation [22,24]. The small
molecules in our structures bind along the b-spine, and because
the parent amyloids contain the same segments, we expect a
similar mode of binding along the spine of the full-length parent
amyloid fibers. Moreover, we anticipate the steric zipper spine
of the parent fibers to be flanked with the rest of the protein
residues in a native-like or unfolded conformation [12,20] and
therefore to contain more solvent channels, or accessible sites
for the binding of the small molecules, compared to the very
compact packing of the steric zipper segments. Consistently,
orange-G, curcumin, and DDNP all bind to, or affect fibrillation
of, full-length fibers [7,9,39].
Molecular Frameworks of Amyloid Binders
Overall, the complexes presented here suggest the nature of two
molecular frameworks for the binding of small molecules to
amyloid fibers. The first molecular framework pertains to site-
specific binders, such as charged compounds that form networks of
interactions with sequence motifs, and is relatively well defined.
The second molecular framework, far less well defined at this
point, pertains to broad-spectrum binders, such as uncharged
aromatic compounds that bind to tube-like cavities between b-
sheets. For binding amyloid deposits in the brain, uncharged
molecules could be more effective because of superior blood-brain-
barrier penetrability. The same frameworks, offering cavities along
b-sheets, might also exist in amyloid oligomers known to be rich in
b-sheets and possibly fiber-like [46], similar to the observed
binding of amyloid markers to b-sheets in non-fibrillar structures
[43,47]. Consistent with this, both oligomers and fibers are
inhibited by similar compounds, including curcumin [7,9].
The specific binding of orange-G allows definition of the
chemical properties of a specific molecular framework. The
prominent feature of amyloid structures is the separation of b-
strands (forming a b-sheet) by ,4.8 A ˚. In structures with strands
packed in an antiparallel orientation, as observed for the
KLVFFA fibers and for a rare mutation in Ab that is associated
with massive depositions of the mutant protein and early onset of
the disease [34,48], the separation of repeating units (2 strands) is
twice as great, ,9.6 A ˚. Orange-G contains two negatively
charged sulfonic acid groups facing the same direction, with the
sulfur atoms spaced ,5A ˚ apart and the oxygen atoms separated
by 4.5–7.5 A ˚. This framework allows the formation of salt links
between the sulfonic acid groups and lysine ammonium ions from
every repeating strand in both KLVFFA (anti-parallel orienta-
tion) and VQIVYK (parallel orientation) fibers (Figures 1 and 4).
This shows that a specific framework includes two charged
moieties spaced either ,4.8 A ˚ or ,9.6 A ˚ apart. The specific
sequence motif of the spine of the fiber and the separation of the
b-strands dictates the signs of the necessary charges in the small
molecule and their separation.
Figure 5. Binding cavities of orange-G within fibers of the VQIVYK segment from the tau protein. Orange-G is bound between steric
zippers of VQIVYK, i.e., internally to a bundle of protofilaments. The VQIVYK segment is located at the third repeat of the tau protein. Since there are
many isoforms of tau, we will number the VQIVYK residues 1–6 for simplicity. Peptide segments, forming b-sheet structures, are shown as arrows and
sticks, colored by atom type with carbons in white. Orange-G carbons are in orange. Surface is shown for peptide atoms contacting the orange-G
molecule (shown as spheres). The view in (A) looks down the fiber axis. The view in (B) is perpendicular to the fiber axis. Only side chains of
interacting residues are shown. The area of the fiber buried by orange-G (Methods) is 309 A ˚2 and about 40% hydrophobic (contributed by the side
chains of Val4 and the carbon chain of Lys6) and 60% polar (contributed by Gln2, Lys6, and the C-terminus). In (B), only one orange-G molecule and
the b-sheets directly contacting it are shown. Zinc atoms are shown as brown spheres. It is noteworthy that interactions between lysine residues, zinc
cations, and negatively charged groups are a motif observed in the Protein Data Bank; for example see [72].
doi:10.1371/journal.pbio.1001080.g005
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essential moiety [22]. The largely apolar KLVFFA segment attracts
the apolar surface of orange-G, stabilizing the binding (Figure 2). In
the complex with VQIVYK, the aromatic rings of orange-G are also
packed against apolar side chains, but the binding is largely mediated
via polar interactions with glutamine and lysine side-chains at the
edges of two steric zippers (Figure 5). The differences in the binding
cavities between the KLVFFA and VQIVYK fibers may account for
the higher molecular stoichiometry within the KLVFFA-orange-G
crystals observed by mass spectrometric analyses, and the corre-
spondingly greater order of this complex (Figures S5–S6).
Despite the lack of atomized electron density for the binding of
curcumin and DDNP in VQIVYK fibers, the location of the
binding cavity is clear. It is narrow, restricting rotation of the small
molecule (Figures 6–7). The atomic groups lining the binding
cavity are about half apolar and half polar (Figure 7). The tube-like
shape favors the binding of uncharged molecules, such as DDNP
and curcumin. The binding site is, however, insufficiently site-
specific to allow for high occupancy and ordered interactions and
is not yet well defined in atomic detail.
Our structures show that different small molecules bind along
the b-spine of amyloid-like fibers. In case fibers contain more than
a single spine, the molecules might bind to multiple sites. This is
more likely for the broad-spectrum hydrophobic compounds but
can also apply for charged compounds. For example, we observed
orange-G to bind to two different steric zippers, of KLVFFA and
VQIVYK, with the commonality of binding to lysine side chains
protruding from the b-sheets.
Figure 6. Models of DDNP and curcumin bound to the VQIVYK fiber based on undifferentiated electron density. Panels A and D are
micro-crystals of VQIVYK co-crystallized with DDNP and curcumin, respectively. In the structure of the complexes with DDNP (B–C) and curcumin (E–
F), VQIVYK is packed in a form having a steric zipper with one b-sheet shifted in relation to the other b-sheet (cartoon arrows). The carbons of VQIVYK
are colored white for one steric zipper and blue for the other. VQIVYK, DDNP, and curcumin are shown as sticks with non-carbon atoms colored by
atom type. Six layers of the fiber are depicted. In panels B and E, the view looks down the fiber axis. In panels C and F, the view is perpendicular to the
fiber axis. In both complexes, only the VQIVYK segment is modeled into the electron density, and in both, there is an apparent difference electron
density Fo-Fc map (shown as mesh, +3s in green and 23s in red) located in the void formed by the shift of the steric zipper. The positive density
(part of the structure that has not been modeled, green mesh) displays a continuous tube-like shape, running along the fiber axis. We attribute this
density to the presence of the small molecules, yet it is too undifferentiated to fit atoms in detail. DDNP (B–C, two molecules are shown) and
curcumin (E–F) (both in magenta carbons) have been computationally docked (Methods) into the structures and fit the location of the positive
density. The unit cell dimension of the crystal along the fiber axis is indicated. The length of both DDNP and curcumin spans multiple unit cells of the
fibril; that is, the dimensions of the small molecule and the fibril unit cell are incommensurate (see Text S1).
doi:10.1371/journal.pbio.1001080.g006
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acid groups, similar to orange-G, but they are spaced ,19 A ˚
apart, which might account for its lack of specificity [44]. In a
recent model, built using NMR constrains, congo-red was
computationally docked to the fungal prion domain HET-
s(218–289), suggesting that the sulfonic acid groups interact with
lysine residues protruding from the sheets [45], similar to orange-
G in our structures. However, in the model, the strands of HET-s
are arranged in an anti-parallel orientation and the sulfonic acid
groups of congo-red interact with every other lysine along the
fiber [45], while orange-G interacts with every single lysine in
both the KLVFFA and VQIVYK complexes (Figures 1 and 4).
Both congo-red and thioflavin T, another known marker, bind to
numerous different b-structures, even in a non-fibrillar form
[43,47]. Despite their limited specificity and low affinity [49,50],
these dyes play a major role in amyloid research because their
binding is detectible via birefringence or fluorescence [51,52]. An
important application of our structures is for the design of new
markers for aggregation that will be more potent and can also be
used in vivo.
The Two Molecular Frameworks and Function
Defining these two molecular frameworks illuminates functional
attributes of specific and broad-spectrum amyloid binders. This
distinction is consistent with competitive kinetic experiments
demonstrating that the binding of FDDNP (the fluoridated analog
of DDNP) to Ab fibrils is displaceable by the uncharged non-
steroidal anti-inflammatory naproxen, but not by the common
charged dyes congo-red and thioflavin T [53]. Moreover, in vitro
FDDNP labels amyloid-like structures in a fashion similar to
congo-red and thioflavin T, providing further evidence for the
broad-spectrum type of binding [54]. Knowledge of both
frameworks can lead to the design of more potent and specific
compounds. These molecules can act as binders and be used as
diagnostics, or serve as inhibitors of aggregation by either
destabilizing steric zippers by wedge action (Figure 1) or binding
between steric zippers preventing higher-order b-sheet interactions
(Figure 4).
In the case of the complexed curcumin and DDNP structures,
we hypothesize that the tube-like cavity along the b-sheets
provides an adequate site for the binding of many compounds of
Figure 7. Binding cavities of DDNP or curcumin within fibers of the VQIVYK segment from the tau protein. VQIVYK segments, forming
parallel b-sheet structures, are shows as arrows and sticks, colored by atom type with carbons in white. Docked DDNP (A and B) and curcumin (C and
D) are shown as spheres with carbons colored magenta. Both small molecules are bound in the void formed within two shifted steric zippers. Surface
is shown for peptide atoms contacting the small molecules. The area of the fiber buried by DDNP or curcumin is 242 A ˚2 or 351 A ˚2, respectively, and is
about 50% hydrophobic (contributed by the side chain of Val1 and Ile3) and 50% polar (contributed by the hydroxyl of Tyr5 and the N-termini). The
view in panels A and C looks down the b-sheets (fiber axis). The view in panels B and D is perpendicular to the fiber axis, with b-strands running
horizontally.
doi:10.1371/journal.pbio.1001080.g007
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the small molecule to drift along the fiber axis, leading to lower
occupancy and a degree of fluidity in the structure. Extrapolating
from our structures, we expect that various aromatic compounds,
such as polyphenols [6], would bind to a variety of amyloid-
forming sequences because of a cylindrical, partially apolar cavity
that forms between the pairs of b-sheets forming the fibers. These
cavities might also provide binding sites for various kinds of apolar
drugs, such as benzodiazepines and anesthetics, explaining some of
the altered pharmacokinetic properties and increased sensitivity
detected in elderly [55].
A subtle implication of our structures for the design of
effective therapeutic treatments is the specificity they reveal of
ligand binding to particular fiber polymorphs (Figure 3).
Various amyloid proteins show diverse fiber morphologies that
are correlated with different patterns of pathology and toxicity
[56,57]. In earlier work, we have suggested that fiber
polymorphism has its molecular basis in different steric zippers
(b-sheet packing) formed by the same sequence [25]. Our new
findings show that different compounds bind to different fiber
polymorphs formed by the same sequence. For example,
orange-G displaces one VQIVYK zipper relative to its mate;
that is, wedges between protofilaments (Figures 3F and 4). In
contrast, both DDNP and curcumin opportunistically bind to
cylindrical cavities at the edges of VQIVYK zippers, in a void
formed within a different VQIVYK b-sheet packing (Figures 3E
and 6). This suggests that each compound binds to only a sub-
population of fibers. Thus, just as cocktails of anti-HIV drugs
are necessary to inhibit different viral strains, a combination of
compounds may be necessary to bind to the several amyloid
polymorphs present.
Conclusions
Four crystal structures of small molecules bound to fiber-
forming segments of the two main Alzheimer’s disease proteins
show common features. The small molecules bind with their long
axes parallel to the fiber axis. The structures reveal a sequence-
specific binder which forms salt links with side-chains of the steric
zipper spines of the fibers and non-specific binders which lie in
cylindrical cavities formed at the edges of several steric zippers.
Small-molecule binding is specific to particular steric-zipper
polymorphs, suggesting that effective Alzheimer’s diagnostics and
therapeutics may have to be mixtures of various compounds to
bind to all polymorphs present. The complexes presented here
suggest routes for structure-based design of combinations of
compounds that can bind to a spectrum of polymorphic
aggregates, to be used as markers of fibers and as inhibitors of
aggregation.
Materials and Methods
Peptide and Compounds
Peptide segments (custom synthesis) were purchased from CS
Bio. Orange-G and curcumin were purchased from Sigma-
Aldrich. DDNP was synthesized as described in [38,58].
Crystallizing Conditions
All crystals were grown at 18uC via hanging-drop vapor
diffusion. All crystals appeared within 1 wk, except the negative
control crystals of VQIVYK+DDNP that took 8 mo to grow.
VQIVYK+orange-G. The drop was a mixture of 10 mM
VQIVYK and 1 mM orange-G in water, and reservoir solution
(0.1 M zinc acetate dehydrate, 18% polyethylene glycol 3350).
The structure was solved to 1.8 A ˚ resolution and contained one
segment, one orange-G, two water molecules, two zinc atoms, and
one acetate molecule in the asymmetric unit.
VQIVYK+DDNP. The drop was a mixture of 6 mM
VQIVYK and 1 mM DDNP in 60% ethanol, and reservoir
solution (0.52 M potassium sodium tartrate, 0.065 M HEPES-Na
pH 7.5, 35% glycerol). The structure was solved to 1.2 A ˚
resolution and contained one segment and three water molecules
in the asymmetric unit.
VQIVYK+DDNP from second crystallization conditions.
The drop was a mixture of 6 mM VQIVYK and 1 mM DDNP in
60% ethanol, and reservoir solution (1.2 M DL-malic acid pH 7.0,
0.1 M BIS-TRIS propane pH 7.0). The structure was solved to
1.65 A ˚ resolution and contained one segment, and three water
molecules in the asymmetric unit.
Negative control crystals to VQIVYK+DDNP. The drop
was a mixture of 6 mM VQIVYK in 60% ethanol and reservoir
solution (0.52 M potassium sodium tartrate, 0.065 M HEPES-Na
pH 7.5, 35% glycerol). The structure was solved to 1.2 A ˚
resolution and contained one segment, and one water molecule
in the asymmetric unit.
VQIVYK+curcumin. The drop was a mixture of 10 mM
VQIVYK and 1 mM curcumin in 80% dimethyl sulfoxide
(DMSO), and reservoir solution (0.1 M Tris.HCl pH 8.5, 70%
(v/v) MPD (2-methyl-2,4-pentanediol)). The structure was solved
to 1.3 A ˚ resolution and contained one segment, and two water
molecules in the asymmetric unit.
Negative control crystals to VQIVYK+curcumin. The
drop was a mixture of 10 mM VQIVYK in 80% DMSO and
reservoir solution (0.1 M Tris.HCl pH 8.5, 70% (v/v) MPD (2-
methyl-2,4-pentanediol)). The structure was solved to 1.3 A ˚
resolution and contained one segment, and one water molecule
in the asymmetric unit.
KLVFFA+orange-G. The drop was a mixture of 10 mM
KLVFFA and 1 mM orange-G in water, and reservoir solution
(10% w/v polyethylene glycol 1,500, 30% v/v glycerol). Another
drop was a mixture of 5 mM KLVFFA and 1 mM orange-G in
water, and reservoir solution (30% w/v polyethylene glycol 1,500,
20% v/v glycerol). The structure was solved to 1.8 A ˚ resolution
and contained four segments, two orange-G molecules, and 11
water molecules in the asymmetric unit.
Negative control crystals to KLVFFA+orange-G. The
drop was a mixture of 10 mM KLVFFA in water, and reservoir
solution (10% w/v polyethylene glycol 1,500, 30% v/v glycerol).
Another drop was a mixture of 5 mM KLVFFA in water, and
reservoir solution (30% w/v polyethylene glycol 1,500, 20% v/v
glycerol). The structure was solved to 2.1 A ˚ resolution and
contained one segment and three water molecules in the
asymmetric unit.
Structure Determination and Refinement
X-ray diffraction data were collected at beamline 24-ID-E of
the Advanced Photon Source (APS), Argonne National Labora-
tory; wavelength of data collection was 0.9792 A ˚.D a t aw e r e
collected at 100 K. Molecular replacement solutions for all
segments were obtained using the program Phaser [59]. The
search models consisted of available structures of the same
segment or geometrically idealized b-strands. Crystallographic
refinements were performed with the program Refmac5 [60].
Model building was performed with Coot [61] and illustrated
with PyMOL [62]. There were no residues that fell in the
disallowed region of the Ramachandran plot. Simulated anneal-
ing composite omit map was generated using CNS [63,64]; 10%
was omitted.
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Three-dimensional (3-D) structures of the small molecules were
generated using Corina (Molecular Networks; http://www.
molecular-networks.com/online_demos/corina_demo) and Chem-
ical Identifier Resolver (http://cactus.nci.nih.gov/translate/).
Additional 3-D conformations were generated using OpenEye
Omega [65]. The small molecule was placed in approximate
location according to the electron density map. The small molecule
was docked to the peptide fibrillar structure using RosettaLigand
[66,67]. The protein side chains were fixed. The generated docked
structures (1,000 for KLVFFA-orange-G and 500 for the rest of the
structures) were further refined using Refmac5 [60] and the 10 best
structures (based on lowest free-R [68]) were analyzed and showed
to be very similar to each other. The best structures were further
optimized and refined and the one with the lowest free-R was
chosen as the final structure.
Solvent Accessible Surface Area, Free Energy, and
Dissociation Constant Calculations
The area buried of the small molecules within the fiber structure
was calculated using Areaimol [69,70] with a probe radius of
1.4 A ˚. The difference between the accessible surface areas of the
fiber structure alone and with the small molecule constitutes the
reported area buried. The Areaimol [69,70] calculations were also
used to report the segment atoms that are in contact with the small
molecules (shown in Figures 2, 5, and 7), and the percentage of
apolar and polar contacts.
Binding energy and corresponding dissociation constant of one
orange-G molecule to the KLVFFA fiber were estimated from the
apolar surface area (contributed by carbon atoms) that is covered
by the interaction and was calculated using Areaimol [69,70]. The
difference between the apolar accessible surface areas of the fiber
structure alone and with the small molecule was added to the
difference between the apolar accessible surface areas of the small
molecule alone and with the fiber. These calculations resulted in
500 A ˚ 2 of apolar surface area covered. The binding energy was
calculated from the formula [71] DG
0=18 cal6A ˚226
mol
21=18 6500 cal/mol =9 kcal/mol. The dissociation constant
was calculated from DG
0=2RTlnK. Thus, K= exp(2DG/RT)
=3 610
27 M =0.3 mM.
Mass Spectrometry Analysis of the Co-Crystals
Liquid chromatography tandem mass spectrometry (LC-
MSMS) was used to measure the molar ratios of the peptide
segments and the small molecules within the crystals. Authentic
samples of the peptides and each of the small molecules were used
to prepare standard response curves. Crystals from each of the
four mixtures of peptides and small compounds were individually
picked (using a sharpened glass capillary) and re-dissolved in 5%–
10% acetonitrile. The samples were divided into two aliquots, one
for the peptide analyses and the other for the small molecule
analyses, and the amount of each component in the samples was
interpolated using the standard curves.
Peptide standards (dry powder of VQIVYK and KLVFFA)
were dissolved in water and prepared in concentrations ranging
from 0.05 mM to 0.01 mM in 0.1% TFA. Aliquots of the
standards and the re-dissolved crystals were separately injected
(50 mL) onto a polymeric reverse phase column (PLRP/S,
26150 mm, 5 mm, 300 A ˚; Varian) equilibrated in Buffer A
(0.1% formic acid in water) and eluted (0.25 mL/min) with an
increasing concentration of Buffer B (0.1% formic acid in
acetonitrile). The effluent from the column was directed to an
Ionspray source attached to a triple quadrupole mass spectrom-
eter (Perkin Elmer/Sciex API III
+) operating under previously
optimized positive ion mode conditions. Data were collected in
the positive ion multiple reaction monitoring (MRM) mode in
which the intensity of specific parentRfragment ion transitions
were recorded (VQIVYK, m/z 749.5R341.3, 749.5R409.4,
749.5R440.3, 749.5R522.5; KLVFFA, 724.4R84, 724.4R
488.3, 362.7R84, 362.7R120.1).
Similar procedures were used for the analyses of the small
molecules. Orange-G was dissolved in water and diluted with 10%
ammonium acetate to concentrations ranging from 2 nM to
20 mM. Solutions of the standard and the re-dissolved crystals
were separately injected (50 mL) onto a silica based reverse phase
column (Supelco Ascentis Express C18, 15062.1 mm, 2.7 mm)
equilibrated in Buffer A (10 mM ammonium acetate) and eluted
(0.2 mL/min) with an increasing concentration of Buffer B
(acetonitrile/Isopropanol 1:1 containing 10 mM ammonium
acetate). The negative ion MRM transitions were m/z
407.1R302.1 and 407.1R222.1.
DDNP was dissolved in 95% ethanol and diluted with 10%
ammonium acetate to concentrations ranging from 2 nM to
20 mM. Solutions of the standards and the re-dissolved crystals
(further diluted with acetonitrile:methanol:water:acetic-acid
(41:23:36:1, v/v/v/v) to ensure dissolution) were separately
injected (50 mL) onto a silica based reverse phase column (Supelco
Ascentis Express C18, 15062.1 mm, 2.7 mm) equilibrated in
Buffer A (10 mM ammonium acetate) and eluted (0.2 mL/min)
with an increasing concentration of Buffer B (acetonitrile/
Isopropanol 1:1 containing 10 mM ammonium acetate). The
positive ion MRM transition was: DDNP 2 m/z 262.1R247.1.
Curcumin was dissolved and diluted in acetonitrile:methanol:-
water:acetic-acid (41:23:36:1, v/v/v/v) to concentrations ranging
from 2 nM to 2 mM. Aliquots of the standards and the re-dissolved
crystals (further diluted with acetonitrile:methanol:water:acetic-
acid (41:23:36:1, v/v/v/v) to ensure dissolution) were injected
(100 mL) onto a silica based reverse phase column (Waters
Symmetry Shield RP18 5 mM, 3.96150 mm) equilibrated in
Buffer A (10 mM ammonium acetate) and eluted (0.5 mL/min)
with an increasing concentration of Buffer B (acetonitrile/
Isopropanol 1:1 containing 10 mM ammonium acetate). The
negative ion MRM transitions were m/z 367.1R173.1,
367.1R149.
Accession Numbers
Structures of KLVFFA complexed with orange-G and
VQIVYK complexed with orange-G are deposited in the Protein
Data Bank (PDB) with accession codes 3OVJ and 3OVL,
respectively (Table S2). The rest of the structures and crystal-
lographic tables are accessible in http://people.mbi.ucla.edu/
meytal/CoCrystalPaper/.
Supporting Information
Figure S1 Chemical structures of the small molecule binders.
(TIF)
Figure S2 The crystal structure of the KLVFFA segment from
Ab complexed with orange-G shows extensive interactions
between two orange-G molecules and the fiber. The KLVFFA
segments are packed as pairs of b-sheets with orange-G bound
internally to the steric zipper. The asymmetric unit of the crystal
contains four peptide segments, two orange-G molecules, and 11
water molecules. Here, four layers of b-strands and two steric
zippers are shown. KLVFFA and orange-G are shown as sticks
with non-carbon atoms colored by atom type. The anti-parallel
strands (cartoon arrows) are alternately colored white and blue,
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orange-G molecules in the asymmetric unit, with carbons in
orange and brown, display similar interactions with the fiber. In
panel A, the view looks down the fiber axis. In panels B–C, the
view is perpendicular to the fiber axis. The sulfonic acid groups of
orange-G form salt links (pink lines) with five lysine residues, four
protruding from facing b-sheets of the steric zipper and one from
the adjacent zipper (only the latter is presented as pink lines in
panel A). Only side chains of residues participating in salt links are
shown. One of the sheets from the adjacent pair and one orange-G
molecule are removed for clarity.
(TIF)
Figure S3 Crystals of the KLVFFA segment from Ab and of the
VQIVYK segment from the tau protein grown with and without
orange-G. (A–B) Micro-crystals of the KLVFFA segment of Ab
grown under identical conditions (Methods) with (A) and without
(B) orange-G. (C–D) Micro-crystals of the VQIVYK segment of
the tau protein grown under identical conditions (Methods) with
(C) and without (D) orange-G.
(TIF)
Figure S4 Crystal structures used as controls for the complexes
of the VQIVYK segment from the tau protein with DDNP and
curcumin. (A) Micro-crystals of VQIVYK co-crystallized with
DDNP; the structure is shown in panel C. (B) Micro-crystals of
VQIVYK crystallized under identical conditions to the crystals in
panel A, lacking DDNP (Methods). The structure is shown in
panel E. (D) The structure of VQIVYK co-crystallized with
DDNP, grown under different crystallization conditions than the
structure shown in panel C (Methods). (F) Micro-crystals of
VQIVYK co-crystallized with curcumin; the structure is shown in
panel G. (I) Micro-crystals of VQIVYK crystallized under
identical conditions to the crystals in panel F, lacking curcumin
(Methods). The structure is shown in panel H. In panels C–E and
G–H, six layers of the VQIVYK fiber are depicted. The
VQIVYK segment pack in parallel b-sheets (represented as
cartoon arrows with white carbons). The view is perpendicular to
the fiber axis, with b-strands running horizontally. Only the
VQIVYK segment was modeled into the electron density. The
difference electron density Fo-Fc map is shown as mesh (+3s in
green and 23s in red), indicating missing atoms in the model.
The crystals grown without the small molecule, either DDNP or
curcumin (panels B and I, respectively), are colorless, whereas the
co-crystals are colored (panels A and F, respectively). Moreover,
the VQIVYKapo structures also lack the positive density (part of
the structure that has not been modeled, green mesh) that we
attribute to the presence of the small molecule (panels E and H
versus panels C and G, respectively). Both structures of VQIVYK
complexed with DDNP, grown under different crystallization
conditions (panels C and D), show a similar, tube-like, positive
electron density map, supporting the attribution of DDNP to this
density.
(TIF)
Figure S5 Electron density maps and simulated annealing
composite omit maps of the KLVFFA segment from Ab
complexed with orange-G. The KLVFFA segments and orange-
G molecules are shown as sticks with non-carbon atoms colored by
atom type. The b-sheets are formed via stacks of anti-parallel
strands, alternately colored with carbons in white and in blue. The
carbons of the orange-G molecules are colored orange. Water
molecules are shown as aqua spheres. The view here is
perpendicular to the fiber axis. (A–C) The electron density 2Fo-
Fc map is shown as grey mesh (1.3s). The difference electron
density Fo-Fc map is shown as mesh (+3s in green and 23s in
red). (D–F) The simulated annealing composite omit 2Fo-Fc map
(10% omitted) is shown as grey mesh (1.3s). Panels B–C and D–E
focus on the two orange-G molecules in the asymmetric unit.
(TIF)
Figure S6 Electron density map of the VQIVYK segment from
the tau protein complexed with orange-G. The VQIVYK segment
and orange-G are shown as sticks with carbon atoms colored grey
and orange, respectively, and non-carbon atoms colored by atom
type. The view in panel A looks down the fiber axis. The view in
panel B is perpendicular to the fiber axis and focuses on orange-G.
The electron density 2Fo-Fc map is shown as grey mesh (1.3s).
The difference electron density Fo-Fc map is shown as mesh (+3s
in green and 23s in red).
(TIF)
Table S1 Screening for co-crystals from mixtures of amyloid-like
segments with small molecules.
(PDF)
Table S2 Data collection and refinement statistics (molecular
replacement).
(PDF)
Text S1 (I) Using computational docking for structure determi-
nation. (II) Incommensurate structures.
(PDF)
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